To encourage drug companies to seek approval for over-the-counter versions of naloxone, an emergency treatment for opioid overdose, the Food and Drug Administration today released model consumer-friendly labels for prospective OTC versions of the drug. FDA-approved versions of naloxone currently require a prescription, which “may be a barrier for people who aren’t under the care of a physician or may be ashamed or even fearful of admitting to issues with substance abuse,” said FDA Commissioner Scott Gottlieb, M.D. Before submitting a new drug application or supplement for an OTC drug product, companies must develop a Drug Facts Label and conduct studies to show that consumers can understand how to use the product without the supervision of a health care professional. “Some stakeholders have identified the requirement to perform these studies as a barrier to development of OTC naloxone products,” Gottlieb said. “To encourage drug companies to enter the OTC market and increase access to naloxone, the FDA took an unprecedented step: we developed a model DFL with easy-to-understand pictograms on how to use the drug. We also conducted label comprehension testing to ensure the instructions were simple to follow.”

Related News Articles

Headline
The National Academies of Sciences Engineering, and Medicine yesterday released recommendations for improving outcomes and metrics associated with four grant…
Headline
The Substance Abuse and Mental Health Services Administration Friday awarded $450 million in grants, including $250 million in emergency COVID-19 funding, to…
Headline
The Centers for Medicare & Medicaid Services recently announced a six-month delay in implementation of its Innovation Center Maternal Opioid Misuse (MOM)…
Headline
Sens. Joe Manchin, D-W.Va., and Shelley Moore Capito, R-W.Va., this week reintroduced the Protecting Jessica Grubb’s Legacy Act (S. 3374), AHA-supported…
Headline
The House Energy and Commerce Health Subcommittee today held a hearing titled “Combatting an Epidemic: Legislation to Help Patients with Substance Use…
Headline
Mallinckrodt Pharmaceuticals today announced an agreement in principle on a settlement to resolve all opioid-related claims against the company in…